CN110950930B - 骨肽及其成骨生理活性确证方法与用途 - Google Patents
骨肽及其成骨生理活性确证方法与用途 Download PDFInfo
- Publication number
- CN110950930B CN110950930B CN201910784028.1A CN201910784028A CN110950930B CN 110950930 B CN110950930 B CN 110950930B CN 201910784028 A CN201910784028 A CN 201910784028A CN 110950930 B CN110950930 B CN 110950930B
- Authority
- CN
- China
- Prior art keywords
- bone peptide
- bone
- peptide
- seq
- simulating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 261
- 210000000988 bone and bone Anatomy 0.000 title claims abstract description 237
- 238000000034 method Methods 0.000 title claims abstract description 60
- 230000001766 physiological effect Effects 0.000 title claims abstract description 40
- 230000002188 osteogenic effect Effects 0.000 title claims description 30
- 238000012790 confirmation Methods 0.000 title abstract description 10
- 230000029087 digestion Effects 0.000 claims abstract description 55
- 210000002784 stomach Anatomy 0.000 claims abstract description 44
- 238000010521 absorption reaction Methods 0.000 claims abstract description 35
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 34
- 230000011164 ossification Effects 0.000 claims abstract description 33
- 239000012528 membrane Substances 0.000 claims abstract description 30
- 108060000903 Beta-catenin Proteins 0.000 claims abstract description 29
- 230000037361 pathway Effects 0.000 claims abstract description 29
- 102000015735 Beta-catenin Human genes 0.000 claims abstract description 27
- 210000000813 small intestine Anatomy 0.000 claims abstract description 27
- 108050003627 Wnt Proteins 0.000 claims abstract description 26
- 210000002919 epithelial cell Anatomy 0.000 claims abstract description 25
- 230000000968 intestinal effect Effects 0.000 claims abstract description 24
- 230000002496 gastric effect Effects 0.000 claims abstract description 22
- 206010070834 Sensitisation Diseases 0.000 claims abstract description 15
- 230000036039 immunity Effects 0.000 claims abstract description 15
- 230000008313 sensitization Effects 0.000 claims abstract description 15
- 235000013376 functional food Nutrition 0.000 claims abstract description 14
- 239000000427 antigen Substances 0.000 claims abstract description 13
- 108091007433 antigens Proteins 0.000 claims abstract description 13
- 102000036639 antigens Human genes 0.000 claims abstract description 13
- 230000009471 action Effects 0.000 claims abstract description 8
- 239000002356 single layer Substances 0.000 claims abstract description 8
- 210000002490 intestinal epithelial cell Anatomy 0.000 claims abstract description 4
- 239000000243 solution Substances 0.000 claims description 53
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 45
- 239000013553 cell monolayer Substances 0.000 claims description 26
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 23
- 210000004027 cell Anatomy 0.000 claims description 22
- 239000000872 buffer Substances 0.000 claims description 20
- 239000012981 Hank's balanced salt solution Substances 0.000 claims description 19
- SDZRWUKZFQQKKV-JHADDHBZSA-N cytochalasin D Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@H]\3[C@]2([C@@H](/C=C/[C@@](C)(O)C(=O)[C@@H](C)C/C=C/3)OC(C)=O)C(=O)N1)=C)C)C1=CC=CC=C1 SDZRWUKZFQQKKV-JHADDHBZSA-N 0.000 claims description 18
- 238000000338 in vitro Methods 0.000 claims description 18
- 230000001079 digestive effect Effects 0.000 claims description 16
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 15
- 239000003112 inhibitor Substances 0.000 claims description 14
- 238000003756 stirring Methods 0.000 claims description 14
- 230000008855 peristalsis Effects 0.000 claims description 12
- 239000007853 buffer solution Substances 0.000 claims description 11
- 102000057297 Pepsin A Human genes 0.000 claims description 10
- 108090000284 Pepsin A Proteins 0.000 claims description 10
- 239000006285 cell suspension Substances 0.000 claims description 10
- 239000001963 growth medium Substances 0.000 claims description 10
- 229940111202 pepsin Drugs 0.000 claims description 10
- 238000012258 culturing Methods 0.000 claims description 9
- 230000007723 transport mechanism Effects 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 108010019160 Pancreatin Proteins 0.000 claims description 8
- 238000011529 RT qPCR Methods 0.000 claims description 8
- 108010004620 glycylsarcosine Proteins 0.000 claims description 8
- VYAMLSCELQQRAE-UHFFFAOYSA-N glycylsarcosine zwitterion Chemical compound OC(=O)CN(C)C(=O)CN VYAMLSCELQQRAE-UHFFFAOYSA-N 0.000 claims description 8
- 229940055695 pancreatin Drugs 0.000 claims description 8
- 238000001262 western blot Methods 0.000 claims description 8
- QDLHCMPXEPAAMD-QAIWCSMKSA-N wortmannin Chemical compound C1([C@]2(C)C3=C(C4=O)OC=C3C(=O)O[C@@H]2COC)=C4[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O QDLHCMPXEPAAMD-QAIWCSMKSA-N 0.000 claims description 8
- QDLHCMPXEPAAMD-UHFFFAOYSA-N wortmannin Natural products COCC1OC(=O)C2=COC(C3=O)=C2C1(C)C1=C3C2CCC(=O)C2(C)CC1OC(C)=O QDLHCMPXEPAAMD-UHFFFAOYSA-N 0.000 claims description 8
- 102000004190 Enzymes Human genes 0.000 claims description 6
- 108090000790 Enzymes Proteins 0.000 claims description 6
- 229940088598 enzyme Drugs 0.000 claims description 6
- 210000000936 intestine Anatomy 0.000 claims description 6
- 239000000758 substrate Substances 0.000 claims description 6
- 238000012360 testing method Methods 0.000 claims description 6
- 238000005406 washing Methods 0.000 claims description 5
- 238000003556 assay Methods 0.000 claims description 4
- 238000011534 incubation Methods 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 238000003766 bioinformatics method Methods 0.000 claims description 3
- 238000001514 detection method Methods 0.000 claims description 3
- 239000002773 nucleotide Substances 0.000 claims description 3
- 125000003729 nucleotide group Chemical group 0.000 claims description 3
- 238000012300 Sequence Analysis Methods 0.000 claims description 2
- 238000010276 construction Methods 0.000 claims description 2
- 210000001819 pancreatic juice Anatomy 0.000 claims description 2
- 102000013814 Wnt Human genes 0.000 abstract description 24
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 23
- 102000004169 proteins and genes Human genes 0.000 abstract description 20
- 102000008186 Collagen Human genes 0.000 abstract description 19
- 108010035532 Collagen Proteins 0.000 abstract description 19
- 229920001436 collagen Polymers 0.000 abstract description 19
- 229920001184 polypeptide Polymers 0.000 abstract description 18
- 230000000975 bioactive effect Effects 0.000 abstract description 12
- 238000011161 development Methods 0.000 abstract description 9
- 244000144972 livestock Species 0.000 abstract description 8
- 244000144977 poultry Species 0.000 abstract description 8
- 230000009102 absorption Effects 0.000 description 29
- 230000000694 effects Effects 0.000 description 28
- 230000014509 gene expression Effects 0.000 description 23
- 108020004414 DNA Proteins 0.000 description 18
- 238000004088 simulation Methods 0.000 description 14
- 230000032258 transport Effects 0.000 description 14
- 210000000963 osteoblast Anatomy 0.000 description 12
- 238000011160 research Methods 0.000 description 12
- 102000035195 Peptidases Human genes 0.000 description 11
- 108091005804 Peptidases Proteins 0.000 description 11
- 238000003825 pressing Methods 0.000 description 11
- 230000007246 mechanism Effects 0.000 description 10
- 241000283690 Bos taurus Species 0.000 description 9
- 230000002093 peripheral effect Effects 0.000 description 9
- 230000035755 proliferation Effects 0.000 description 9
- 125000003275 alpha amino acid group Chemical group 0.000 description 8
- 210000002449 bone cell Anatomy 0.000 description 8
- 230000004663 cell proliferation Effects 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 239000004365 Protease Substances 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 102000007079 Peptide Fragments Human genes 0.000 description 5
- 108010033276 Peptide Fragments Proteins 0.000 description 5
- 239000002778 food additive Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 235000019833 protease Nutrition 0.000 description 5
- 230000003827 upregulation Effects 0.000 description 5
- 208000001132 Osteoporosis Diseases 0.000 description 4
- -1 Oxterix Proteins 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 231100000683 possible toxicity Toxicity 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 102000001301 EGF receptor Human genes 0.000 description 3
- 108060006698 EGF receptor Proteins 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- KLGQSVMIPOVQAX-UHFFFAOYSA-N XAV939 Chemical compound N=1C=2CCSCC=2C(O)=NC=1C1=CC=C(C(F)(F)F)C=C1 KLGQSVMIPOVQAX-UHFFFAOYSA-N 0.000 description 3
- 229940124532 absorption promoter Drugs 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000012202 endocytosis Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 235000019419 proteases Nutrition 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000015775 Core Binding Factor Alpha 1 Subunit Human genes 0.000 description 2
- 108010024682 Core Binding Factor Alpha 1 Subunit Proteins 0.000 description 2
- 241000700108 Ctenophora <comb jellyfish phylum> Species 0.000 description 2
- 108010058546 Cyclin D1 Proteins 0.000 description 2
- 102000005593 Endopeptidases Human genes 0.000 description 2
- 108010059378 Endopeptidases Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 2
- 102100038104 Glycogen synthase kinase-3 beta Human genes 0.000 description 2
- 101001124867 Homo sapiens Peroxiredoxin-1 Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 108090000301 Membrane transport proteins Proteins 0.000 description 2
- 102000003939 Membrane transport proteins Human genes 0.000 description 2
- 102100029139 Peroxiredoxin-1 Human genes 0.000 description 2
- KKEYFWRCBNTPAC-UHFFFAOYSA-N Terephthalic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 101150109862 WNT-5A gene Proteins 0.000 description 2
- 102000043366 Wnt-5a Human genes 0.000 description 2
- 108700020483 Wnt-5a Proteins 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000003262 anti-osteoporosis Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 230000009061 membrane transport Effects 0.000 description 2
- 210000000110 microvilli Anatomy 0.000 description 2
- 210000004409 osteocyte Anatomy 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 229910021642 ultra pure water Inorganic materials 0.000 description 2
- 239000012498 ultrapure water Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 206010016946 Food allergy Diseases 0.000 description 1
- GRIRDMVMJJDZKV-RCOVLWMOSA-N Gly-Asn-Val Chemical compound [H]NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O GRIRDMVMJJDZKV-RCOVLWMOSA-N 0.000 description 1
- CAVKXZMMDNOZJU-UHFFFAOYSA-N Gly-Pro-Ala-Gly-Pro Natural products C1CCC(C(O)=O)N1C(=O)CNC(=O)C(C)NC(=O)C1CCCN1C(=O)CN CAVKXZMMDNOZJU-UHFFFAOYSA-N 0.000 description 1
- SSFWXSNOKDZNHY-QXEWZRGKSA-N Gly-Pro-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)CN SSFWXSNOKDZNHY-QXEWZRGKSA-N 0.000 description 1
- OOCFXNOVSLSHAB-IUCAKERBSA-N Gly-Pro-Pro Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 OOCFXNOVSLSHAB-IUCAKERBSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- 102000046014 Peptide Transporter 1 Human genes 0.000 description 1
- 229940122907 Phosphatase inhibitor Drugs 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 description 1
- 108091006594 SLC15A1 Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 239000006180 TBST buffer Substances 0.000 description 1
- 108010049264 Teriparatide Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- PMZXXNPJQYDFJX-UHFFFAOYSA-N acetonitrile;2,2,2-trifluoroacetic acid Chemical group CC#N.OC(=O)C(F)(F)F PMZXXNPJQYDFJX-UHFFFAOYSA-N 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 229940062527 alendronate Drugs 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 230000037118 bone strength Effects 0.000 description 1
- 159000000007 calcium salts Chemical group 0.000 description 1
- 230000004656 cell transport Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 101150044072 cn gene Proteins 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 230000002121 endocytic effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 208000006881 esophagitis Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 108010082406 peptide permease Proteins 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108010087846 prolyl-prolyl-glycine Proteins 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 230000007065 protein hydrolysis Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 229940089617 risedronate Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- OGBMKVWORPGQRR-UMXFMPSGSA-N teriparatide Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 OGBMKVWORPGQRR-UMXFMPSGSA-N 0.000 description 1
- 229960005460 teriparatide Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000032895 transmembrane transport Effects 0.000 description 1
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 description 1
- 229960004276 zoledronic acid Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6851—Quantitative amplification
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (6)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910784028.1A CN110950930B (zh) | 2019-08-23 | 2019-08-23 | 骨肽及其成骨生理活性确证方法与用途 |
NL2026294A NL2026294B1 (en) | 2019-08-23 | 2020-08-19 | Ossotide, and method for confirming osteogenesis physiological activity and use thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910784028.1A CN110950930B (zh) | 2019-08-23 | 2019-08-23 | 骨肽及其成骨生理活性确证方法与用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110950930A CN110950930A (zh) | 2020-04-03 |
CN110950930B true CN110950930B (zh) | 2021-09-07 |
Family
ID=69976246
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910784028.1A Active CN110950930B (zh) | 2019-08-23 | 2019-08-23 | 骨肽及其成骨生理活性确证方法与用途 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN110950930B (zh) |
NL (1) | NL2026294B1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE1027448B1 (fr) * | 2020-11-15 | 2022-02-08 | Institute Of Food Science And Tech Chinese Academy Of Agricultural Sciences | Un procédé d'évaluation de la structure-activité des polypeptides à activité ostéogénique |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007087131A2 (en) * | 2006-01-05 | 2007-08-02 | The Johns Hopkins University | Peptide prodrugs |
CN107523600A (zh) * | 2017-09-29 | 2017-12-29 | 中国农业科学院农产品加工研究所 | 促进人成骨细胞增殖的骨胶原多肽的制备方法与用途 |
CN107541538A (zh) * | 2017-08-10 | 2018-01-05 | 江苏大学 | 体外模拟胃肠消化制备胶原凝胶抗氧化多肽液的方法 |
CN109715656A (zh) * | 2015-08-25 | 2019-05-03 | 伊斯迪德股份公司 | 用于诱导组织形成的化合物及其用途 |
CN110136774A (zh) * | 2019-05-22 | 2019-08-16 | 中国农业科学院农产品加工研究所 | 成骨活性多肽的构效评价方法 |
-
2019
- 2019-08-23 CN CN201910784028.1A patent/CN110950930B/zh active Active
-
2020
- 2020-08-19 NL NL2026294A patent/NL2026294B1/en active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007087131A2 (en) * | 2006-01-05 | 2007-08-02 | The Johns Hopkins University | Peptide prodrugs |
CN109715656A (zh) * | 2015-08-25 | 2019-05-03 | 伊斯迪德股份公司 | 用于诱导组织形成的化合物及其用途 |
CN107541538A (zh) * | 2017-08-10 | 2018-01-05 | 江苏大学 | 体外模拟胃肠消化制备胶原凝胶抗氧化多肽液的方法 |
CN107523600A (zh) * | 2017-09-29 | 2017-12-29 | 中国农业科学院农产品加工研究所 | 促进人成骨细胞增殖的骨胶原多肽的制备方法与用途 |
CN110136774A (zh) * | 2019-05-22 | 2019-08-16 | 中国农业科学院农产品加工研究所 | 成骨活性多肽的构效评价方法 |
Non-Patent Citations (3)
Title |
---|
Wnt信号通路在骨质疏松防治中的研究进展;何晓君等;《中国会议》;20140704;277-279 * |
利用Caco-2细胞模型研究肠道可吸收乳清肽的结构特征;周慧敏;《中国优秀硕士学位论文全文数据库 工程科技Ⅰ辑》;中国学术期刊(光盘版)电子杂志社;20190415(第04期);B024-106 * |
牦牛骨粉制备及其抗骨质疏松活性研究;秦晓洁;《中国优秀硕士学位论文全文数据库 工程科技Ⅰ辑》;中国学术期刊(光盘版)电子杂志社;20190815(第08期);B024-117 * |
Also Published As
Publication number | Publication date |
---|---|
CN110950930A (zh) | 2020-04-03 |
NL2026294B1 (en) | 2022-07-07 |
NL2026294A (en) | 2020-10-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103168236B (zh) | 用于膜电位测定的光遗传学探针 | |
CN107326002A (zh) | Dna‑细胞缀合物 | |
CN102146135A (zh) | 一种重组类人胶原蛋白及其生产方法 | |
CN102282169A (zh) | 表达破骨细胞相关受体的细胞活性和分化的调节 | |
Alexandrushkina et al. | Cell sheets from adipose tissue MSC induce healing of pressure ulcer and prevent fibrosis via trigger effects on granulation tissue growth and vascularization | |
CN106086029A (zh) | 一种长非编码rna及其在诊断/治疗胃癌中的应用 | |
CN110950930B (zh) | 骨肽及其成骨生理活性确证方法与用途 | |
CN106867968A (zh) | Ybx1稳定表达的smcc-7721细胞系及构建方法 | |
CN111304171B (zh) | 烟碱乙酰胆碱受体靶向性的过表达circDYM的外泌体及其制备方法与应用 | |
CN109576297A (zh) | 一种含wsb1基因启动子和报告基因的重组质粒及其构建方法和应用 | |
CN113244413B (zh) | 一种mRNA剂型的骨关节炎药物制剂及其制备方法和应用 | |
CN117069864B (zh) | 一种具有修复活性的重组纤连-胶原融合蛋白及其制备方法与应用 | |
CN102898514B (zh) | 重组人神经生长因子缺失突变体及其制备方法和用途 | |
CN105803085B (zh) | 一种检测骨关节炎的分子标记物及其用途 | |
CN105457028B (zh) | 在骨形成中发挥调控作用的应力敏感性microRNA | |
Wang et al. | Isolation and characterization of bovine bone collagen peptides with stimulatory effects on mineralization in osteoblasts | |
Fang et al. | Recombinant COL6 α2 as a self-organization factor that triggers orderly nerve regeneration without guidance cues | |
Frtús et al. | Hepatic tumor cell morphology plasticity under physical constraints in 3D cultures driven by YAP–mTOR axis | |
CN109652555A (zh) | 一种诊治恶性肿瘤的分子标志物 | |
CN106589137A (zh) | 穿膜肽‑人β防御素3融合蛋白及其制备方法和应用 | |
CN102517195A (zh) | 基于光敏感基因的细胞分泌物生产系统和方法 | |
CN117736272B (zh) | 一种具有促成骨功能的生物活性多肽 | |
CN117510619B (zh) | 一种创新空间结构的重组ⅲ型人源化胶原蛋白微球及其设计、制备工艺和应用 | |
CN105755148B (zh) | 一种检测骨关节炎的试剂盒及其方法 | |
CN113373117B (zh) | 一种过表达miR-13474工程化外泌体及其制备方法与应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20220621 Address after: 011517 north of Yanjing South Street, Shengle economic Park, Helingeer County, Hohhot City, Inner Mongolia Autonomous Region Patentee after: INNER MONGOLIA MENGTAI BIOLOGICAL ENGINEERING CO.,LTD. Address before: 100193 No.2 Yuanmingyuan West Road, Haidian District, Beijing Patentee before: INSTITUTE OF FOOD SCIENCE AND TECHNOLOGY, CHINESE ACADEMY OF AGRICULTURAL SCIENCES |
|
TR01 | Transfer of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Confirmation Method and Application of Bone Peptide and Its Osteogenic Physiological Activity Effective date of registration: 20230629 Granted publication date: 20210907 Pledgee: Inner Mongolia Bank Co.,Ltd. Hohhot Ordos East Street Branch Pledgor: INNER MONGOLIA MENGTAI BIOLOGICAL ENGINEERING CO.,LTD. Registration number: Y2023150000102 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
CP03 | Change of name, title or address |
Address after: 011517 north of Yanjing South Street, Shengle economic Park, Helingeer County, Hohhot City, Inner Mongolia Autonomous Region Patentee after: Mengpeptide Pharmaceutical Co.,Ltd. Country or region after: China Address before: 011517 north of Yanjing South Street, Shengle economic Park, Helingeer County, Hohhot City, Inner Mongolia Autonomous Region Patentee before: INNER MONGOLIA MENGTAI BIOLOGICAL ENGINEERING CO.,LTD. Country or region before: China |